Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.

Grade Last Price % Change Price Change
F 26.51 -0.04% -0.01
IOVA closed down 0.04 percent on Tuesday, May 11, 2021, on 1.3 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical IOVA trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Stochastic Buy Signal Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -0.04%
Older End-of-Day Signals for IOVA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 13 hours ago
Up 2% about 13 hours ago
2x Volume Pace about 14 hours ago
Gap Down Closed about 15 hours ago
Rose Above Lower Bollinger Band about 15 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Iovance Biotherapeutics, Inc. Description

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immune System Immunotherapy Oncology Cancer Immunotherapy Cancer Treatments Melanoma Antineoplastic Drugs Cancer Cell Cell Therapy Head And Neck Cancer Checkpoint Inhibitor Solid Tumor Adoptive Cell Transfer Immunotherapy Product Metastatic Melanoma Cancer Immunotherapy Product Lymphocytes National Cancer Institute Cancer Immunotherapy Products Head And Neck Cancers Immunotherapy Products Ocular Melanoma Breast And Lung Cancer Pembrolizumab Treatment Of Metastatic Melanoma Tumor Infiltrating Lymphocytes

Is IOVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 54.2081
52 Week Low 24.67
Average Volume 1,896,765
200-Day Moving Average 36.93
50-Day Moving Average 31.35
20-Day Moving Average 30.34
10-Day Moving Average 29.59
Average True Range 1.94
ADX 17.87
+DI 16.51
-DI 31.15
Chandelier Exit (Long, 3 ATRs ) 27.73
Chandelier Exit (Short, 3 ATRs ) 30.89
Upper Bollinger Band 33.80
Lower Bollinger Band 26.89
Percent B (%b) -0.05
BandWidth 22.78
MACD Line -1.21
MACD Signal Line -0.81
MACD Histogram -0.3989
Fundamentals Value
Market Cap 3.89 Billion
Num Shares 147 Million
EPS -1.31
Price-to-Earnings (P/E) Ratio -20.27
Price-to-Sales 0.00
Price-to-Book 8.12
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.87
Resistance 3 (R3) 29.76 28.54 29.31
Resistance 2 (R2) 28.54 27.68 28.59 29.12
Resistance 1 (R1) 27.52 27.15 28.03 27.63 28.94
Pivot Point 26.30 26.30 26.55 26.35 26.30
Support 1 (S1) 25.28 25.44 25.79 25.39 24.08
Support 2 (S2) 24.06 24.91 24.11 23.90
Support 3 (S3) 23.04 24.06 23.71
Support 4 (S4) 23.15